Conditions: Carcinoma, Renal Cell
Keywords: Sorafenib Nexavar Metastatic RCC Renal Cell Carcinoma Unresectable RCC
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 39
Healthy volunteers: no

Brief summary:
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.

Detailed description:

Arms:
arm 1: 400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)

Interventions: intervention 1: Sorafenib (Nexavar, BAY43-9006)
Intervention descriptions: intervention 1: 400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)

Protocol document: